Extrait

The primary objective of the trial is to assess the pharmacokinetics and relative bioavailability of tapentadol following administration of 3 prototype tapentadol PR granule formulations (test formulations) each containing 25 mg tapentadol, compared to 1 tablet of Palexia® PR 25 mg (reference formulation) under fasted and fed conditions. The main pharmacokinetic target parameters are Cmax and AUC0-t for tapentadol.

Critère d'inclusion

• No medical condition to be investigated

Liens

• ictrp
• euctr